Literature DB >> 32099361

The Protective Roles of Vitamin E and α-Lipoic Acid Against Nephrotoxicity, Lipid Peroxidation, and Inflammatory Damage Induced by Gold Nanoparticles.

Mohamed Anwar K Abdelhalim1, Huda Ay Qaid1, Yanallah H Al-Mohy1, Magdi Mohamed Ghannam1.   

Abstract

BACKGROUND: Recently, use of nanotechnology in biomedical applications such as drug delivery and diagnostic and therapeutic tools has increased greatly. This study evaluated gold nanoparticle (GNPs)-induced nephrotoxic effects in rats in vivo, and examined protective effects of alpha-lipoic acid (α-Lip) and Vitamin E (Vit E) against nephrotoxicity, lipid peroxidation, and inflammatory kidney damage induced by GNPs.
MATERIALS AND METHODS: Twenty-four male Wistar-Kyoto rats (220-240 g, 12 weeks old) were dosed with 50 μL of 10 nm GNPs administered intraperitoneally with or without 200 mg/kg/day Vit E or 200 mg/kg/day α-Lip. Serum was prepared for biochemical analyses. Kidney function was evaluated through measurement of creatinine (CR), uric acid (URIC), and blood urea nitrogen (BUN). Oxidative stress and lipid peroxidation were evaluated by measurement of reduced glutathione (GSH) and malondialdehyde (MDA) in kidney tissue homogenates. RESULTS AND
CONCLUSIONS: The results showed a significant rise in serum kidney function biomarkers including urea, URIC, CR, and BUN in GNP-treated rats compared to normal control rats. Furthermore, GNPs led to decreased GSH and elevated MDA levels. Vit E or α-Lip supplementation showed a beneficial effect against nephrotoxicity, lipid peroxidation, and inflammatory kidney damage induced by GNPs. This study suggests that use of natural antioxidants in combination with GNPs may be a useful tool in preventing GNPs toxicity.
© 2020 Abdelhalim et al.

Entities:  

Keywords:  Vitamin E; alpha-lipoic acid; gold nanoparticles; lipid peroxidation; natural antioxidants; nephrotoxicity

Mesh:

Substances:

Year:  2020        PMID: 32099361      PMCID: PMC6999539          DOI: 10.2147/IJN.S192740

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


Introduction

Nanoparticles (NPs) are potentially dangerous chemical substances that adhere to cell membranes and permeate animal organs. Nanoparticle surfaces can be changed and adjusted to the environmental transformation.1 Distribution of NPs in the liver, spleen, cerebrum, heart, and kidney may result in impaired function. A previous study showed that the dimensions and surface area of nanoparticles are important factors in increased reactive oxygen species (ROS) production2. Exposure to GNPs can result in inflammation, death of tubular epithelial cells, increased capillary permeability, blood loss, and inflammatory cell infiltration.3–8 Vit E is a critical fat-soluble antioxidant that supports mitosis, immune function, speeds of blood clotting, and serves as a natural defense against oxidative stress in tissues. Vit E also contributes to cell membrane function, elasticity, and integrity.9,10 Alpha-lipoic acid is a potent antioxidant and is a substrate for the pyruvate dehydrogenase complex found in mitochondria of hepatic, renal, and cardiac tissues. α-Lip can be reduced to dihydrolipoic acid, which has ROS scavenging activity, and maintains GSH and vitamins C and E, which are exogenous, in the reduced state.11 Prevention of toxicity induced by GNPs in vivo has not been reported. Therefore, this study aims to confirm nephrotoxicity, lipid peroxidation, and inflammatory kidney damage caused by GNPs, and to assess the role of Vit E and α-Lip acid in inhibiting or preventing alterations induced by GNPs in the kidney organ.

Materials and Methods

GNPs and Antioxidants

Size and morphology of 10nm GNPs (products MKN-Au-010; M K IPEX Corp; Divn MK Nano, CANADA) have shown spherical shape with mean size 9.45 ± 1.33 nm as calculated from the images taken by transmission electron microscope (TEM). The GNPs have been distributed in homogenous way through the solution. Vit E and α-Lip were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). The Vit E dose was 100mg/Kg BW/day, and the α-Lip acid dose was 200mg/Kg BW/day, according to Al-Rasheed et al., 2014.12

Animals

Twenty-four 12-week-old Wistar-Kyoto male rats (220–240 g) were acquired from the College of Pharmacy, Animal Centre, KSU. The rats were kept in cages under standard conditions (22±5°C temperature, 55±5% humidity, 12 hrs light/dark cycle). Rats were fed a regular rodent diet. The KSU Animal Use Committee approved the animal experiments, and all experiments were conducted in accordance with the committee’s guidelines approved by KSU Local Animal Care.

Experimental Design

Rats were acclimatized for 2 days, fasted for 24 hrs before injection, and randomly divided into four groups (n=6 each). The first group (G1; healthy rats) did not receive GNPs and served as a control. The second group (G2) was treated daily by intraperitoneal injection with 50 µL of 10 nm GNPs for 7 consecutive days. The third group (G3) was treated with 10 nm GNPs (50 µL) plus 100 mg/Kg BW/day of Vit E for 7 consecutive days. The fourth group (G4) was treated with 10 nm GNPs (50 µL) plus 200 mg/Kg BW/day of α-Lip for 7 consecutive days.

Blood Sampling and Tissue Preparation

Twenty-four hours after the final dose, rats were denied access to food for 12–14 hrs, then sacrificed. Blood samples were obtained from each rat and placed into Pasteurized tubes for serum separation. Samples were centrifuged at 3,000 rcf for 10 mins, and serum was stored at −80°C until use. Kidney tissues were collected and harvested by the midline incision technique, washed in ice-cold iso-osmotic saline, homogenized, and frozen at −80°C until use.

Serum Kidney Function Biomarkers

To assay kidney function, blood urea nitrogen (BUN), creatinine (CR), and uric acid (URIC) levels in serum were determined using a biochemical auto-analyser (Type 7170, Hitachi).

Oxidative Stress Biomarkers

Reduced Glutathione (GSH) Level Determination

The level of reduced glutathione (GSH) in the renal tissues was evaluated enzymatically according to Griffith, 1980.13 Tissues were homogenized in 0.2 M ice-cold perchloric acid containing EDTA (0.01%), then centrifuged at 10,000 rcf for 5 mins. One hundred microliters of supernatant was added to a spectrophotometer cuvette containing 100 µL of 6 mM 5,5-dithiobis-2-nitrobenzoic acid, 800 µL of 0.3 mM reduced NADPH, and 10 µL of 50 units/mL glutathione reductase prepared fresh in pH 7.5 phosphate buffer. Absorbance was determined at 412 nm for 120 mins at 30°C. Glutathione was assayed by comparing absorbance of the test solution to a glutathione standard.

Determination of Malondialdehyde (MDA)

Malondialdehyde (MDA) levels were measured as a marker of fatty acid peroxidation index in various organs using the spectrophotometric method described by Hochstein and Utley (1967). Tissues were weighed and homogenized (10% w/v) in 0.15 M frozen potassium chloride (KOH) with a potter homogenizer and motor-driven Teflon pestle. One milliliter of tissue homogenate was incubated at 37ºC for 2 hrs in a shaker. One milliliter of 10% (w/v) trichloroacetic acid added to the homogenate, and the mixture was centrifuged at 3000 rcf for 10 mins. One milliliter of the supernatant was mixed with one mL of 0.67% (w/v) 2-thiobarbituric acid and placed in a hot water bath for 10 mins, then allowed to cool. Following cooling, 1 mL of distilled water was added. The absorbance was determined at 535 nm, and malondialdehyde level was calculated using tetraethoxypropane (TEP) as a standard.

Statistical Analysis

Data obtained were presented as mean ± SE. To test for the difference between the means, one-way analysis of variance (ANOVA) was used, followed by Bonferroni multiple differences post hoc test, with significance determined by p≤0.05 and **p≤0.001.

Results

Figure 1 shows a major increase in serum creatinine level in the GNPs group (0.57 ± 0.02 mg/dL) compared to the control group (0.43 ± 0.03 mg/dL). Group 3 (GNPs + Vit E) and group 4 (GNPs + α-Lip) significantly reduced the level of creatinine to 0.42 ± 0.02 mg/dL and 0.43 ± 0.02 mg/dL, respectively. Administration of α-Lip or Vit E with GNPs blocked GNPs-induced increases in creatinine.
Figure 1

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on serum creatinine level in rats. *a represents significance between the control group and the GNPs groups (p<0.05). *b represents significance between the GNPs and the other groups (p<0.05).

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on serum creatinine level in rats. *a represents significance between the control group and the GNPs groups (p<0.05). *b represents significance between the GNPs and the other groups (p<0.05). Figure 2 shows serum urea level of control (G1), GNPs (G2), G3, and G4 rats. Serum urea in G1 was 18.08 ± 0.93 mg/dL. After 7 days of intraperitoneal administration of GNPs, the mean level of urea increased significantly to 23.28 ± 1.03 mg/dL (**p<0.01), contributing to renal damage. Administration of Vit E + GNPs (G3) and α-Lip + GNPs (G4) significantly reduced the GNPs-induced elevation of urea to 19.52 ± 0.88 mg/dL, 20.22 ± 0.62 mg/dL, respectively.
Figure 2

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on serum urea level in rats. **a significant value (p˂0.001). *b represents significance between the GNPs and the other groups (p<0.05), **b significant value p˂0.001: the data were highly significant at this value.

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on serum urea level in rats. **a significant value (p˂0.001). *b represents significance between the GNPs and the other groups (p<0.05), **b significant value p˂0.001: the data were highly significant at this value. Figure 3 shows increased uric acid levels in the GNPs group (1.55 ± 0.75 mg/dL) compared with the control group (1.10 ± 0.98 mg/dL). Administration of Vit E + GNPs (G3) and α-Lip + GNPs (G4) significantly reduced kidney uric acid levels to 1.05 ± 0.85 mg/dL and 1.13 ± 0.65 mg/dL, respectively, compared to administration of GNPs alone.
Figure 3

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on serum uric acid level in rats. *a represents significance between the control group and the GNPs groups (p<0.05). *b represents significance between the GNPs and the other groups (p<0.05), **b significant value p˂0.001: the data were highly significant at this value.

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on serum uric acid level in rats. *a represents significance between the control group and the GNPs groups (p<0.05). *b represents significance between the GNPs and the other groups (p<0.05), **b significant value p˂0.001: the data were highly significant at this value. Figure 4 shows a significant decrease in kidney GSH level in the GNPs group to 24.20 ± 0.02 μg/mL compared to 56.85 ± 0.02 μg/mL in the control group. Administration of Vit E + GNPs (G3) and α-Lip + GNPs (G4) significantly elevated GSH levels to 56.12 ± 0.01 μg/mL and 53.15 ± 0.02 μg/mL, respectively, compared to GNPs alone.
Figure 4

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on kidney GSH level in rats.**a significant value (p˂0.001). *b represents significance between the GNPs and the other groups (p<0.05), **b significant value p˂0.001: the data were highly significant at this value.

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on kidney GSH level in rats.**a significant value (p˂0.001). *b represents significance between the GNPs and the other groups (p<0.05), **b significant value p˂0.001: the data were highly significant at this value. Figure 5 shows a significant increase in the lipid peroxidation product, malondialdehyde (MDA), in rat kidney tissues in response to GNP (0.27 ± 0.03 μmoles/mL) compared to control (0.07 ± 0.01 μmoles/mL). Co-administration of Vit E + GNPs (G3) and α-Lip + GNPs (G4) significantly reduced MDA levels to 0.09 ± 0.03 μmoles/mL and 0.12 ± 0.02 μmoles/mL, respectively.
Figure 5

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on kidney Malondialdehyde level in rats. *a represents significance between the control group and the GNPs groups (p<0.05). *b represents significance between the GNPs and the other groups (p<0.05).

Effect of GNPs, GNPs + Vit E, and GNPs + α-Lip on kidney Malondialdehyde level in rats. *a represents significance between the control group and the GNPs groups (p<0.05). *b represents significance between the GNPs and the other groups (p<0.05). Figure 6 shows histopathological studies that give more evidences of the nephrotoxic effect of GNPs and the protective effect of Vit E and α-Lip.
Figure 6

Sections in cortex of the kidney (H&E x 200). (A) Normal control rats (G1) show renal corpuscle consists of glomerulus (G) and a two-layered glomerular Bowman’s capsule (BC) that encloses glomerulus; the proximal convoluted tubules (PCT) and distal convoluted tubules (DCT). (B) GNPs-treated rats (G2) show inflammatory cells infiltration, mainly in the interstitial tissue (arrows), vacuolar degeneration surrounding PCT and DCT, tubule necrosis (star), dilation and vacuolar degeneration in PCT and DCT. (C) GNPs + Vitamin E (G3) shows normal renal corpuscle surrounded by normal tubules. (D) GNPs + α-lipoic acid (G4) shows vacuolar degeneration in PCT and DCT.

Sections in cortex of the kidney (H&E x 200). (A) Normal control rats (G1) show renal corpuscle consists of glomerulus (G) and a two-layered glomerular Bowman’s capsule (BC) that encloses glomerulus; the proximal convoluted tubules (PCT) and distal convoluted tubules (DCT). (B) GNPs-treated rats (G2) show inflammatory cells infiltration, mainly in the interstitial tissue (arrows), vacuolar degeneration surrounding PCT and DCT, tubule necrosis (star), dilation and vacuolar degeneration in PCT and DCT. (C) GNPs + Vitamin E (G3) shows normal renal corpuscle surrounded by normal tubules. (D) GNPs + α-lipoic acid (G4) shows vacuolar degeneration in PCT and DCT.

Discussion

NPs absorbed into the blood and are cleared by the kidney.14 This study confirmed nephrotoxic effects of GNPs. Our research shows that GNPs significantly elevated URIC, BUN, and CR levels compared to the control group. GSH levels in kidney tissues were significantly decreased, while MDA levels were significantly increased. In serum from rats injected with GNPs, significant increases in CR and BUN levels compared to control confirmed nephrotoxicity (p<0.05). Vit E and α-Lip significantly reduced serum CR, URIC, and BUN levels compared to rats administered GNPs. Vit E disrupts free radical reactions, resulting in formation of antioxidant radicals that are only moderately reactive. As a result, Vit E scavenges free radicals.15 Vit E quenches fatty acid peroxidation in membranes due to its radical scavenging ability.16 Thus, Vit E serves an essential role in renal tissues against peroxidative injury.17 Vit E supplementation may reduce oxidative stress, and also may be useful in reducing heart disease linked to chronic kidney failure. In vivo and in vitro studies have shown that Vit E provides a defense against fatty acid peroxidation and inhibits metal-mediated damage. α-Lip increases concentrations of hepatic cysteine and glutathione. α-Lip can reduce oxidized vitamin C, helping to maintain antioxidant status. α-Lip can boost production of glutathione, the foremost antioxidant in human cells.12,18,19 Decrease oxidative stress resulting α-Lip or Vit E may be responsible for their anti-inflammatory effects. GSH in kidney tissues decreased significantly after administering of GNPs. In contrast, GSH increased significantly after Vit E or α-Lip administration. GSH functions as a scavenger of poisons and free radical-generated species. GSH can also compensate for Vit E deficiency. Previous studies evaluated GSH levels in animals injected with Vit E or α–Lip after zinc nanoparticles injection.12,13,16–18

Conclusions

This study highlights the nephrotoxic effects induced by intraperitoneal administration of GNPs as confirmed by significant increases in serum kidney function markers such as URIC, CR, and BUN. In addition to a significant increase in the fatty acid peroxidation biomarker MDA, GNPs also resulted in significant reduction in the oxidative stress biomarker GSH. Administration of Vit E or α-Lip significantly reduced inflammatory kidney damage, lipid peroxidation, and oxidative stress, as determined by reduced serum markers, elevated tissue levels of GSH, and reduced tissue MDA. Our findings showed that Vit E and α-Lip are highly potent antioxidants that can protect against the kidney dysfunction, inflammatory damage, lipid peroxidation, and oxidative stress.
  17 in total

1.  Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease.

Authors:  Luis F Ramos; Jane Kane; Ellen McMonagle; Phuong Le; Pingsheng Wu; Ayumi Shintani; Talat Alp Ikizler; Jonathan Himmelfarb
Journal:  J Ren Nutr       Date:  2010-12-24       Impact factor: 3.655

Review 2.  Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones.

Authors:  P J Randle; A L Kerbey; J Espinal
Journal:  Diabetes Metab Rev       Date:  1988-11

3.  Antioxidants vitamin C and vitamin e for the prevention and treatment of cancer.

Authors:  Ian D Coulter; Mary L Hardy; Sally C Morton; Lara G Hilton; Wenli Tu; Di Valentine; Paul G Shekelle
Journal:  J Gen Intern Med       Date:  2006-07       Impact factor: 5.128

4.  Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver.

Authors:  M S Moron; J W Depierre; B Mannervik
Journal:  Biochim Biophys Acta       Date:  1979-01-04

5.  Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.

Authors:  O W Griffith
Journal:  Anal Biochem       Date:  1980-07-15       Impact factor: 3.365

6.  Endosulfan-induced cardiotoxicity and free radical metabolism in rats: the protective effect of vitamin E.

Authors:  Suna Kalender; Yusuf Kalender; Ayşe Ogutcu; Meltem Uzunhisarcikli; Dilek Durak; Fatma Açikgoz
Journal:  Toxicology       Date:  2004-10-01       Impact factor: 4.221

7.  Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice.

Authors:  Meike L Schipper; Gopal Iyer; Ai Leen Koh; Zhen Cheng; Yuval Ebenstein; Assaf Aharoni; Shay Keren; Laurent A Bentolila; Jianquing Li; Jianghong Rao; Xiaoyuan Chen; Uri Banin; Anna M Wu; Robert Sinclair; Shimon Weiss; Sanjiv S Gambhir
Journal:  Small       Date:  2009-01       Impact factor: 13.281

Review 8.  Role of oxidative damage in toxicity of particulates.

Authors:  Peter Møller; Nicklas R Jacobsen; Janne K Folkmann; Pernille H Danielsen; Lone Mikkelsen; Jette G Hemmingsen; Lise K Vesterdal; Lykke Forchhammer; Håkan Wallin; Steffen Loft
Journal:  Free Radic Res       Date:  2010-01

9.  Prophylactic role of α-lipoic acid and vitamin E against zinc oxide nanoparticles induced metabolic and immune disorders in rat's liver.

Authors:  N M Al-Rasheed; N M Al-Rasheed; N A Abdel Baky; L M Faddah; A J Fatani; I H Hasan; R A Mohamad
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

10.  Applications of nanoparticles in biology and medicine.

Authors:  OV Salata
Journal:  J Nanobiotechnology       Date:  2004-04-30       Impact factor: 10.435

View more
  8 in total

1.  Maackiain Protects the Kidneys of Type 2 Diabetic Rats via Modulating the Nrf2/HO-1 and TLR4/NF-κB/Caspase-3 Pathways.

Authors:  Jiahong Guo; Junying Li; Hua Wei; Zhaozhi Liang
Journal:  Drug Des Devel Ther       Date:  2021-10-14       Impact factor: 4.162

Review 2.  Vitamin Supplementation Protects against Nanomaterial-Induced Oxidative Stress and Inflammation Damages: A Meta-Analysis of In Vitro and In Vivo Studies.

Authors:  Dongli Xie; Jianchen Hu; Zhenhua Yang; Tong Wu; Wei Xu; Qingyang Meng; Kangli Cao; Xiaogang Luo
Journal:  Nutrients       Date:  2022-05-26       Impact factor: 6.706

3.  The relationship between reactive oxygen species, DNA fragmentation, and sperm parameters in human sperm using simplified sucrose vitrification with or without triple antioxidant supplementation.

Authors:  Theesit Juanpanich; Tayita Suttirojpattana; Rangsun Parnpai; Teraporn Vutyavanich
Journal:  Clin Exp Reprod Med       Date:  2022-05-30

4.  Clofibrate, a Peroxisome Proliferator-Activated Receptor-Alpha (PPARα) Agonist, and Its Molecular Mechanisms of Action against Sodium Fluoride-Induced Toxicity.

Authors:  Ademola Adetokunbo Oyagbemi; Olumuyiwa Abiola Adejumobi; Theophilus Aghogho Jarikre; Olumide Samuel Ajani; Ebunoluwa Racheal Asenuga; Idayat Titilayo Gbadamosi; Aduragbenro Deborah A Adedapo; Abimbola Obemisola Aro; Blessing Seun Ogunpolu; Fasilat Oluwakemi Hassan; Olufunke Olubunmi Falayi; Iyanuoluwa Omolola Ogunmiluyi; Temidayo Olutayo Omobowale; Oluwatosin Adetola Arojojoye; Olufunke Eunice Ola-Davies; Adebowale Benard Saba; Adeolu Alex Adedapo; Benjamin Obukowho Emikpe; Matthew Olugbenga Oyeyemi; Sanah Malomile Nkadimeng; Lyndy Joy McGaw; Prudence Ngalula Kayoka-Kabongo; Oluwafemi Omoniyi Oguntibeju; Momoh Audu Yakubu
Journal:  Biol Trace Elem Res       Date:  2021-04-24       Impact factor: 3.738

Review 5.  An Overview of the Beneficial Role of Antioxidants in the Treatment of Nanoparticle-Induced Toxicities.

Authors:  Vladimir Mihailovic; Jelena S Katanic Stankovic; Dragica Selakovic; Gvozden Rosic
Journal:  Oxid Med Cell Longev       Date:  2021-11-15       Impact factor: 6.543

6.  The Protective Effect of α-Lipoic Acid against Gold Nanoparticles (AuNPs)-Mediated Liver Damage Is Associated with Upregulating Nrf2 and Suppressing NF-κB.

Authors:  Ghedeir M Alshammari; Mohamed Anwar Abdelhalim; Mohammed S Al-Ayed; Laila Naif Al-Harbi; Mohammed Abdo Yahya
Journal:  Nutrients       Date:  2022-08-14       Impact factor: 6.706

7.  Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-synuclein aggregates.

Authors:  Maria Elena Piersimoni; Xiangyu Teng; Anthony E G Cass; Liming Ying
Journal:  Nanoscale Adv       Date:  2020-10-21

8.  Evaluation of the protective roles of alpha-lipoic acid supplementation on nanomaterial-induced toxicity: A meta-analysis of in vitro and in vivo studies.

Authors:  Xiaogang Luo; Dongli Xie; Tong Wu; Wei Xu; Qingyang Meng; Kangli Cao; Jianchen Hu
Journal:  Front Nutr       Date:  2022-09-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.